Zynerba Pharmaceuticals, Inc. (ZYNE)
(Delayed Data from NSDQ)
$11.45 USD
+0.35 (3.15%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.45 USD
+0.35 (3.15%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Zynerba (ZYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try a different approach? Tap five stocks with increasing P/E ratios. These include CuriosityStream (CURI), Root (ROOT), LendingClub (LC), Manitex International (MNTX) and Zynerba Pharmaceuticals (ZYNE).
Zynerba (ZYNE) Loses 29.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Inside the Top-Performing ETFs of Q1
by Sweta Killa
Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.
Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.79, moving +1.34% from the previous trading session.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study
by Zacks Equity Research
Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.
Implied Volatility Surging For Zynerba Pharmaceuticals (ZYNE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba
by Zacks Equity Research
Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba
Is This a Buying Opportunity in the Marijuana Stocks?
by Tracey Ryniec
The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?
Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZYNE) Outperforming Other Medical Stocks This Year?
Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.47, moving +1.76% from the previous trading session.
Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $3.83, marking a +0.17% move from the previous day.
Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed at $4.18 in the latest trading session, marking a -1.88% move from the prior day.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel.
Zynerba Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Zynerba Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $5, moving -0.79% from the previous trading session.
Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.20, marking a -0.38% move from the previous day.
Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.70, marking a -0.35% move from the previous day.
Ride the Cannabis Wave With These 3 Stocks
by Urmimala Biswas
Here we discuss three best stocks in the emerging cannabis space.
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals